2017;33(2):243-252. 431. Chao TF, Liu CJ, Wang KL, et al. Incidence and prediction of ischemic stroke among atrial brillation patients with end-stage renal disease requiring dialysis. Heart Rhythm. 2014;11(10):1752- 1759. 432. Carrero JJ, Evans M, Szummer K, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial brillation. Jama. 2014;311(9):919-928. 433. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial brillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015;36(5): 297-306. 434. Bonde AN, Lip GY, Kamper AL, et al. Net clinical bene t of antithrombotic therapy in patients with atrial brillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64(23):2471-2482. 435. Bonde AN, Lip GY, Kamper AL, et al. Effect of reduced renal function on time in therapeutic range among anticoagulated atrial brillation patients. J Am Coll Cardiol. 2017;69(6):752-753. 436. Harel Z, Chertow GM, Shah PS, et al. Warfarin and the risk of stroke and bleeding in patients with atrial brillation receiving dialysis: a systematic review and meta-analysis. Can J Cardiol. 2017;33(6):737-746. 437. Lau YC, Proietti M, Guiducci E, Blann AD, Lip GY. Atrial brillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol. 2016;68(13):1452-1464. 438. Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C. The de nition of valvular and non-valvular atrial brillation: results of a physicians survey. Europace. 2014. 439. Authors/Task Force m, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779. 440. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. 